1.27
Precedente Chiudi:
$1.11
Aprire:
$1.1
Volume 24 ore:
4.67M
Relative Volume:
2.14
Capitalizzazione di mercato:
$127.20M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7697
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+36.32%
1M Prestazione:
+37.87%
6M Prestazione:
-60.00%
1 anno Prestazione:
-73.70%
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.265 | 127.20M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
230.40 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-01-06 | Downgrade | Stifel | Buy → Hold |
2023-01-06 | Downgrade | Truist | Buy → Hold |
2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
2022-12-15 | Iniziato | Goldman | Sell |
2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
2022-10-10 | Iniziato | Canaccord Genuity | Buy |
2022-08-18 | Ripresa | Wells Fargo | Overweight |
2022-07-28 | Iniziato | Needham | Hold |
2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | Iniziato | Robert W. Baird | Neutral |
2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-12-07 | Iniziato | Cowen | Outperform |
2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-04-26 | Ripresa | Jefferies | Buy |
2021-02-26 | Iniziato | BofA Securities | Buy |
2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
2020-05-13 | Iniziato | H.C. Wainwright | Buy |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | Reiterato | Mizuho | Buy |
2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2019-11-12 | Iniziato | SunTrust | Buy |
2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
2019-10-01 | Iniziato | Stifel | Buy |
2019-08-09 | Iniziato | BTIG Research | Buy |
2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
2019-07-12 | Iniziato | Oppenheimer | Outperform |
2019-06-13 | Iniziato | Mizuho | Buy |
2019-06-07 | Iniziato | ROTH Capital | Neutral |
2019-05-31 | Iniziato | Guggenheim | Buy |
2019-05-24 | Ripresa | Citigroup | Buy |
2019-03-28 | Iniziato | SVB Leerink | Outperform |
2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
2018-11-05 | Iniziato | Jefferies | Buy |
2018-08-01 | Iniziato | Citigroup | Buy |
2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®
Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa
Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com
Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire
American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com
FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
FATE Stock Plummets to 52-Week Low at $0.87 Amidst Sharp Decline - Investing.com
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada
Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):